Companies /Healthcare

Arvinas Inc

NASDAQ: ARVN Biotechnology
$6.76
▼ $0.06 (−0.88%) today
Markets open · 1:48pm ET

24/7 Wall St. View

ARVN at a Glance

Valuation
Market cap
$446.6M
Profitability
Revenue (TTM)
$275.3M
Profit margin
-3.5%
EPS (TTM)
$-0.08
Price
52-week range
$6 – $15
Street target
$14.00

Headquartered in New Haven, CT Fiscal year ends December NASDAQ: ARVN arvinas.com

About Arvinas

Arvinas is a clinical-stage biotechnology company that develops targeted protein degradation therapies using its PROTAC (PROteolysis TArgeting Chimera) platform. Its drugs are designed to harness the body's natural protein disposal system to eliminate disease-causing proteins rather than merely inhibit them.

With Pfizer, Arvinas developed vepdegestrant (VEPPANU), an ER degrader for breast cancer. It received FDA approval in May 2026 as the first approved PROTAC. It has since been out-licensed to Rigel Pharmaceuticals, from which Arvinas receives royalties and is eligible for milestones.

The AR degrader luxdegalutamide is out-licensed to Novartis and is in Phase 2 prostate cancer trials.

Arvinas's wholly owned clinical pipeline includes:
- **ARV-393:** BCL6 degrader for relapsed/refractory non-Hodgkin lymphoma, alone and with glofitamab.
- **ARV-6723:** HPK1 degrader, an immuno-oncology asset for advanced solid tumors, alone and with pembrolizumab.
- **ARV-027:** polyQ-AR degrader for spinal-bulbar muscular atrophy (Kennedy's disease).
- **ARV-102:** brain-penetrant LRRK2 degrader for progressive supranuclear palsy and Parkinson's disease.

The company is seeking to out-license its KRAS G12D degrader ARV-806. Revenue currently comes from partner royalties, milestones and license payments. Updated

ARVN Coverage

Frequently Asked Questions

What does Arvinas do?

Arvinas is a clinical-stage biotechnology company that develops targeted protein degradation therapies using its PROTAC (PROteolysis TArgeting Chimera) platform. Its drugs are designed to harness the body's natural protein disposal system to eliminate disease-causing proteins rather than merely inhibit them.

What is the ARVN stock price target?

The Wall Street consensus 12-month price target for ARVN is $14.00. ARVN price prediction →